Vagotomv attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide in rats

LEVENTE KAPÁS, MICHAEL K. HANSEN, HEE-YOON CHANG, AND JAMES M. KRUEGER
Department of Physiology and Biophysics, University of Tennessee, Memphis, Tennessee 38163

Kapás, Levente, Michael K. Hansen, Hee-Yoon Chang, and James M. Krueger. Vagotomv attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide (LPS) in rats. Am. J. Physiol. 274 (Regulatory Integrative Comp. Physiol. 43): R406–R411, 1998.—The role of the vagus nerve in the somnogenic and pyrogenic effects of lipopolysaccharide (LPS) was studied in rats. Control rats (n = 8) and rats subjected to bilateral subdiaphragmal vagotomy (VX; n = 9) were injected with 100 µg/kg ip LPS at the beginning of the dark period. Sleep and brain temperature (Tbr) were recorded for 23 h after the injections. LPS caused increases in sleep duration of the non-rapid eye movement sleep (NREMS) for 12 h after the injection in control rats. Sleep intensity, as indicated by the slow-wave activity (SWA) of the electroencephalogram during non-rapid eye movement sleep (NREMS), was suppressed. LPS elicited biphasic Tbr responses: an initial hypothermia was followed by increases in Tbr that lasted for ~20 h. In vagotomized rats, the NREMS responses to LPS were blunted. The magnitude of the LPS-induced NREMS increases was about one-half of that seen in control rats, and these sleep responses lasted only for 6 h. LPS did not affect SWA in VX animals. VX completely abolished the hypothermic responses to LPS and shortened the duration of the hyperthermia. The results suggest that the subdiaphragmal vagi play an important, but not exclusive, role in the somnogenic and pyrogenic actions of intraperitoneally injected LPS.

thermoregulation; electroencephalogram slow-wave activity; vagus nerve

SYSTEMIC INFECTIONS, peripheral lipopolysaccharide (LPS) treatments, and several cytokines all induce central nervous system-related symptoms of the acute phase response, such as increased non-rapid eye movement sleep (NREMS) and fever (21). Although LPS itself does not enter the brain after systemic administration (6, 29), there are several possible mechanisms by which microbial products and the immune system may affect brain function. Numerous central effects induced by peripheral injection of LPS or cytokines are inhibited by vagus nerve transection, suggesting a neural communication pathway for systemic cytokines between the periphery and the brain. For example, interleukin-1 (IL-1)-induced fever (34), taste aversion (12), and depression in food-motivated behavior (2), as well as LPS-induced gene expression (11, 23, 33), behavioral changes (23), adrenocorticotropic hormone responses (11), hyperalgesia (35), and fever (30) are blocked or attenuated by vagotomv.

Sensory signals arriving via vagus afferents affect cerebrocortical activity and sleep stages. Electrical vagal stimulation causes "vagoaortic sleep" in encephale isolé preparations (reviewed in Ref. 28). Depending on the stimulus parameters, vagal stimulation may cause electroencephalogram (EEG) synchroni-
compared values obtained on the baseline day to those
variance (ANOVA) for repeated measures was performed. We

treatment within a group of animals, two-way analysis of
summed for each 10-s epoch. Hourly average activities (µV2)
were then calculated for the NREMS epochs. The delta
activity during NREMS (also called slow-wave activity (SWA))
is often regarded as a measurement of sleep intensity. On
the baseline day, the average SWA was computed across the
total 23 h for each rat to obtain a reference value for each
animal. SWA for each hour on the baseline and test days was
then expressed as a percent of that reference value. Group
averages were calculated hourly and also for the entire dark
and light periods.

Experimental protocol. On the baseline day, the animals
were injected with isotonic NaCl intraperitoneally. On the
test day, the rats received 100 µg/kg ip LPS. The baseline and
test days were separated by 3 recovery days when saline was
injected intraperitoneally at dark onset, but sleep was not
recorded. The order of the baseline and test days was
counterbalanced. EEG, EMG, and Tbr were recorded for 23 h
after injections. Because of the malfunction of one thermistor,
the animal number for Tbr in the VX group is eight. Two rats
each from group were excluded from the FFT analysis because their EEGs were contaminated with artifacts; the
vigilance states of these animals, however, could be deter-
mined.

Statistical analysis. To analyze the effects of the LPS
treatment within a group of animals, two-way analysis of
variance (ANOVA) for repeated measures was performed. We
compared values obtained on the baseline day to those
obtained on the LPS day for each animal. Tbr, or SWA values
averaged in 1-h time blocks. Separate ANOVAs were
performed for the first 6-h, the second 6-h, and the last 11-h
period. When ANOVA indicated significant treatment effects,
the Student-Newman-Keuls (SNK) test was performed a
posteriori (Table 2).

The average nighttime and daytime sleep amounts, epi-
sonosis numbers and durations, and SWA after saline and LPS
treatments within the same groups were compared using
daired t-test; the comparisons between VX and control groups
were done using SNK test (Table 1).

Differences in baseline sleep or Tbr between the control
and VX animals as well as the differences in the effects of LPS
between two groups were determined using two-way ANOVA
across the 23-h recording period on values averaged in 1-h
time blocks.

RESULTS

Effects of LPS in control rats. LPS induced excess
NREMS in the dark period after a latency of 1 h (Fig. 1
and Tables 1 and 2). NREMS was significantly
increased both in the first and second 6-h postinjection
periods by 55.2 ± 10.6 and 14.0 ± 2.8%, respectively.
This effect was mainly due to a significant increase in
the numbers of NREMS epochs in the night. In the light

period, NREMS returned to the baseline levels. The
amount of REMS, the number of REMS epochs, and the
average duration of REMS episodes were not affected
by LPS. During the first 12 h after LPS injection, there
was a tendency toward decreased SWA. In the subse-
quently 4-h period after injections samples in 10-min intervals. Horizontal
dark bar: dark period of the day. *Significant difference from baseline
(P < 0.05, Student-Newman-Keuls test); †significant change from
baseline (P < 0.05, paired t-test). LPS induced increases in NREMS,
decreases in SWA, and biphasic Tbr responses in control rats.
average number and duration of NREMS and REMS episodes did not differ significantly between control and VX rats in either photoperiod. The Tbr of the vagotomized rats on the baseline day was significantly lower by -0.6-1.2°C than observed in the controls [ANOVA between the effects of LPS in control vs. VX rats in either photoperiod. The Tbr of the vagotomized rats in either photoperiod. The Tbr of the vagotomized rats in either photoperiod.]

**DISCUSSION**

Effects of LPS in normal rats. Our results are consistent with the previous findings that systemic administration of LPS increases the time spent in NREMS (3, 20, 22, 27). This increase is due to increased number of NREMS episodes (22; and present results). Previously, a suppression of REMS was also reported in the first 6-12 h after LPS injection (20, 22, 27). In our experiments, there was a tendency toward decreased REMS 2-3 h after injection and throughout the light period but these changes were not statistically significant. It is likely that the effects of LPS on sleep depend on the activity of sleep mechanisms at the time of the LPS treatment. We injected LPS at the beginning of the dark period when the amounts of REMS are the lowest in rats. In the previous studies, LPS was injected in the dark period after LPS injection [ANOVA for Tbr, the effects of LPS in control vs. VX rats, treatment effects across hours 1-12: F(1,168) = 4.24, P < 0.05; across hours 13-23: F(1,154) = 12.16, P < 0.05]. There were two major differences, however, between the effects of LPS on Tbr in control and VX animals. First, Tbr did not decrease in the first 1-2 h after LPS injection and, second, Tbr did not remain elevated throughout the 23-h recording period, it returned to the baseline level by the beginning of the light phase of the day in VX rats.

**Table**

**Table 1. Effects of saline and LPS on the amounts of REMS, NREMS, the number and average durations of NREMS and REMS epochs, and on Tbr in the dark and the light period of the day**

<table>
<thead>
<tr>
<th></th>
<th>Control Dark</th>
<th>Control Light</th>
<th>Vagotomized Dark</th>
<th>Vagotomized Light</th>
</tr>
</thead>
<tbody>
<tr>
<td>NREMS, min</td>
<td>226.9 ± 11.3</td>
<td>290.1 ± 7.9*</td>
<td>284.9 ± 7.7</td>
<td>314.4 ± 11.7</td>
</tr>
<tr>
<td>REMS, min</td>
<td>54.9 ± 5.6</td>
<td>57.2 ± 3.5</td>
<td>58.7 ± 2.7</td>
<td>61.3 ± 3.2</td>
</tr>
<tr>
<td>NREMS number of epochs</td>
<td>141.2 ± 2.5</td>
<td>191.5 ± 6.4*</td>
<td>191.3 ± 5.7</td>
<td>197.2 ± 6.2</td>
</tr>
<tr>
<td>REMS number of epochs</td>
<td>294 ± 2.5</td>
<td>312 ± 2.5</td>
<td>340 ± 1.9</td>
<td>428 ± 1.4</td>
</tr>
<tr>
<td>NREMS epoch length, min</td>
<td>1.63 ± 0.03</td>
<td>1.52 ± 0.06</td>
<td>1.71 ± 0.07</td>
<td>1.60 ± 0.06</td>
</tr>
<tr>
<td>REMS epoch length, min</td>
<td>1.84 ± 0.09</td>
<td>1.86 ± 0.07</td>
<td>2.03 ± 0.05</td>
<td>1.91 ± 0.07</td>
</tr>
<tr>
<td>SWA</td>
<td>100.0 ± 0.0</td>
<td>93.2 ± 1.7*</td>
<td>100.0 ± 0.0</td>
<td>93.8 ± 0.9*</td>
</tr>
</tbody>
</table>

Values are means ± SE. LPS, lipopolysaccharide; NREMS, non-rapid eye movement sleep; SWA, slow-wave activity. *Significant difference from saline treatment (P < 0.05, Student-Newman-Keuls test). †Significant difference from corresponding saline treatment in the control group (P < 0.05, Student-Newman-Keuls test).

**Table 2. Effects of LPS on the amount of sleep, SWA, and Tbr in control and vagotomized rats: statistical results**

<table>
<thead>
<tr>
<th></th>
<th>Control Hours 1-6*</th>
<th>Control Hours 7-12†</th>
<th>Control Hours 13-23‡</th>
<th>Vagotomized Hours 1-6*</th>
<th>Vagotomized Hours 7-12†</th>
<th>Vagotomized Hours 13-23‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>NREMS</td>
<td>F (1,7) = 43.16</td>
<td>F (1,7) = 26.63</td>
<td>F (1,7) = 1.35</td>
<td>F (1,8) = 11.29</td>
<td>F (1,8) = 3.34</td>
<td>F (1,8) = 22.66</td>
</tr>
<tr>
<td></td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.05</td>
<td>NS</td>
<td>P &lt; 0.05</td>
<td>NS</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>REMS</td>
<td>F (1,7) = 0.31</td>
<td>F (1,7) = 2.28</td>
<td>F (1,7) = 3.14</td>
<td>F (1,8) = 1.56</td>
<td>F (1,8) = 0.43</td>
<td>F (1,8) = 0.62</td>
</tr>
<tr>
<td></td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>SWA</td>
<td>F (1,5) = 0.86</td>
<td>F (1,5) = 4.17</td>
<td>F (1,5) = 10.53</td>
<td>F (1,6) = 1.84</td>
<td>F (1,6) = 0.03</td>
<td>F (1,6) = 3.26</td>
</tr>
<tr>
<td></td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Tbr</td>
<td>F (1,7) = 0.07</td>
<td>F (1,7) = 7.48</td>
<td>F (1,7) = 66.07</td>
<td>F (1,7) = 1.52</td>
<td>F (1,7) = 13.79</td>
<td>F (1,7) = 4.05</td>
</tr>
<tr>
<td></td>
<td>NS</td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.05</td>
<td>NS</td>
<td>P &lt; 0.05</td>
<td>NS</td>
</tr>
</tbody>
</table>

Two-way ANOVA for repeated measures was performed between the test (LPS) and corresponding baseline (saline) days. *ANOVA across the 1st 6-h period after injections on values averaged in 1-h intervals. †ANOVA across the 2nd 6-h period after injections on values averaged in 1-h intervals. ‡ANOVA across the 13- to 23-h period after injections on values averaged in 1-h intervals. P < 0.05: significant LPS effects. NS, nonsignificant difference between the effects of LPS and saline.
light phase of the day when the amount of spontaneously occurring REMS is high. It is likely that the REMS mechanisms are more sensitive to the suppressive effects of LPS when they are highly activated in the light period in rats. Conversely, the NREMS-generating mechanisms may be more sensitive to the stimulatory effects of LPS at night when their spontaneous activity is low. Consistent with this notion, when LPS was injected in rats in the light period, it did not (16) or only slightly stimulated NREMS (3) or its NREMS-inducing effects appeared only after a latency of 12 h, i.e., in the subsequent dark period (22).

We observed suppressed sleep intensity, as indicated by the SWA of the EEG, during NREMS in response to LPS. In humans, SWA did not change after LPS injection (27). In rats, a biphasic SWA response to LPS was previously found: an initial increase was followed by suppressed SWA (22). It is likely that the timing of the LPS treatment is an important factor also in the SWA responses. IL-1 is a somnogenic cytokine that is assumed to play a key role in mediating the sleep-promoting effects of LPS (reviewed in Ref. 21). IL-1 primarily induces NREMS without stimulating SWA when injected at dark onset in rats (26); we injected LPS also at this time point. However, if IL-1 is given at the beginning of the light period, it stimulates SWA without promoting sleep or it even suppresses NREMS in higher doses (26). In the study where a transient increase in SWA was found after LPS injection (22), the treatments were given at light onset and, similar to the effects of IL-1, not only sleep intensity increased but also the time spent in NREMS decreased in the light period in response to LPS injection. These findings indirectly support the hypothesis that IL-1 may be a key mediator of LPS-induced sleep and SWA responses. 

Rats respond to systemic LPS injection with hypothermia (10, 32) and/or fever depending on the dose, ambient temperature, initial body temperature, and rat strain (9, 31). These complex thermoregulatory effects suggest that LPS can activate both pyretic and antipyretic mechanisms in rats; cytokines are thought to play a central role in both of these mechanisms (18). LPS elicits a biphasic thermoregulatory response in the dose range of 20–500 µg/kg LPS if the animals are kept at subthermoneutral ambient temperature (below 28–30°C). The first phase is a dose-dependent decrease in body temperature, which is followed by fever (9). Our results are fully consistent with these findings. The time course of the hypothermic response in our control animals was very similar to that reported previously after systemic administration of 100 µg/kg LPS; the decrease reached its maximum ~90 min after the injection and the temperature returned to control level ~120 min after the LPS treatment (9).

The effects of VX on the sleep and T_{br} responses to LPS. VX attenuated the sleep and febrile responses to LPS, suggesting that the subdiaphragmatic vagi play a significant role in the somnogenic and thermoregulatory effects of intraperitoneally administered LPS. Similarly, VX attenuated the sleep responses to systemic injections of IL-1β (15). It is possible that somnogenic cytokines, such as IL-1 and tumor necrosis factor (TNF) are released in the periphery in response to LPS and act directly on specific receptors on the vagus to promote NREMS. The presence of IL-1α binding sites in the vagal paraganglia (13) and the finding that intraportal injection of IL-1β stimulates the afferent activity of the vagus (25) support this possibility. It cannot be ruled out, however, that the vagus may serve a permissive role rather than be a direct target for cytokines in the somnogenic effects of LPS. The finding that VX did not block the first phase of febrile or somnogenic effects of LPS indicates that the role of subdiaphragmatic vagi is not exclusive in the somnogenic and pyrogenic actions of LPS. It is likely that LPS also triggers sleep and thermoregulatory mechanisms acting at sites different from the subdiaphragmatic vagi. For example, significant amounts of intraperitoneally injected LPS and/or the cytokines produced in the periphery in response to LPS enter the systemic circulation; e.g., blood levels of LPS and cytokines are higher after LPS treatment (27, 29). When plasma levels of cytokines and LPS are relatively high, they may enter the brain in amounts sufficient to directly activate central somnogenic and pyrogenic structures in addition to the vagus nerve. This may take place at sites where the blood-brain barrier is missing, e.g., the organum vasculosum laminae terminalis or area postrema or via cytokine transporters (1).
Alternatively, circulating LPS and cytokines may stimulate the production of one or more low-molecular-weight messengers outside the blood-brain barrier. These messengers, in turn, cross the blood-brain barrier and act on neurons in the brain. One possible candidate for such a diffusible messenger is NO. LPS induces the excess production of NO by activating inducible NO synthase in endothelial cells (reviewed in Ref. 24). NO, when injected in the cerebral ventricle in the form of NO donor substances, induces increases in NREMS (17). It is possible, therefore, that LPS and/or cytokines produced in response to LPS trigger the production of NO in brain endothelia, and increased brain NO levels will ultimately induce NREMS.

A large fraction of systemically injected LPS is still present in the liver 6–24 h after the injection (29). Liver Kupffer cells produce significant amounts of cytokines on stimulation with LPS (reviewed in Ref. 7). It is possible that the levels of circulating cytokines 6–12 h after the LPS injection are not high enough to activate central mechanisms directly. However, the elevated levels of cytokines produced in the liver in response to residual levels of LPS could be sufficient to activate afferenters locally, therefore eliciting delayed sleep and febrile responses.

The hypothermic response to LPS was completely absent in the VX animals. Peripheral macrophage product(s) (9), possibly TNF-\(\alpha\) (8), play a key role in LPS-induced hypothermia. It is hypothesized that TNF activates central antipyretic mechanisms, such as the septal arginine vasopressin system (8). Several effects of TNF-\(\alpha\) are mediated by the vagus nerve (12), it is possible therefore that its activating effects on central antipyretic mechanisms also require intact vagus nerves. Alternatively, since LPS hypothermia involves reduced thermogenesis (9) and VX rats already have reduced \(T_{\text{th}}\), it is possible that the mechanism that LPS acts on to suppress thermogenesis is already activated in VX animals.

The technical assistance of Ying Wang is gratefully acknowledged. This work was supported by National Institutes of Health Grants NS-30514 (to L. Kapaś) and NS-25378, NS-27250, and NS-31453 (to J. M. Krueger) and the Fordham University (12–07–1257).

Current address of J. M. Krueger: Dept. of Veterinary Comparative Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Washington State Univ., Pullman, WA 99164-6520.

Current address of and address for reprint requests: L. Kapaś, Dept. of Biological Sciences, Fordham Univ., 441 E. Fordham Road, Bronx, NY 10458.

Received 6 August 1997; accepted in final form 3 November 1997.

REFERENCES


23. Layé, S., R. M. Bluthé, S. Kent, C. Combe, C. Médina, P. Parnet, K. Kelley, and R. Dantzer. Subdiaphragmatic va-


